913849-17-9

Usage

Uses

Used in Flavoring and Fragrance Industry:
Ethyl 2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanoate is used as a flavoring agent and fragrance in various consumer products for its distinctive fruity and sweet scent. It enhances the sensory experience of products, making them more appealing to consumers.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, Ethyl 2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanoate is utilized in the production of various medications. Its unique chemical properties make it a valuable component in the development of drugs, contributing to their efficacy and stability.
Used in Agrochemical Industry:
Ethyl 2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanoate also finds application in the agrochemical industry. It is used in the formulation of various agrochemical products, such as pesticides and herbicides, to improve their performance and effectiveness in agricultural practices.
Used in Other Industrial Products:
This chemical compound is also employed in the manufacturing of other industrial products, where its unique properties contribute to the final product's quality and performance. Its versatility allows it to be integrated into a wide range of applications, enhancing the overall characteristics of the products it is used in.
It is important to handle Ethyl 2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanoate with caution, as prolonged or excessive exposure may lead to adverse health effects. Proper safety measures should be taken during its use to ensure the well-being of individuals involved in its production, handling, and application.

InChI:InChI=1/C12H14F3NO3/c1-4-18-10(17)11(2,3)19-9-6-5-8(7-16-9)12(13,14)15/h5-7H,4H2,1-3H3

Upstream product

• 52334-81-3 2-chloro-5-trifluoromethylpyridine 
• 600-00-0 ethyl 2-bromoisobutyrate 
• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 

Downstream Products

• 605680-62-4 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoic acid 
• 605681-37-6 2-ethoxy-5-trifluoromethylpyridine 
• 876365-72-9 3-{(1S,2S)-1-(4-chlorobenzyl)-2-[(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoyl)amino]propyl}benzamide 
• 876365-70-7 N-[(1Z)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylprop-1-en-1-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 701977-00-6 N-[(1R,2R)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 701977-09-5 taranabant 

Relevant academic research and scientific papers

SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS

Disclosed are compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts. These compounds are suitable as Poly (ADP-ribose) polymerase- 1 inhibitors (PARP-1 inhibitors).

PRO-DRUGS OF TERTIARY ALCOHOLS

The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1 ) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid- 1 (CB 1) receptor. In particular, compounds of the

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.

COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.